Table 4. Clinicopathological features and protein expression by KRAS mutation.
| Factor (N) | KRAS mutation [N(%)] | OR (95% CI) | |
| Absent | Present* | ||
| Age | |||
| ≤40 (27) | 23 (19.83) | 4 (3.45) | 0.342 (0.085–1.379) |
| >40 (89)* | 84 (72.41) | 5 (4.31) | |
| Grade | |||
| 1/2 (96) | 91 (78.45) | 5 (4.31) | 4.550 (1.102–18.788)** |
| 3 (20)* | 16 (13.79) | 4 (3.45) | |
| Tumor invasion | |||
| T1/T2 (9) | 8 (6.9) | 1 (0.86) | 0.646 (0.071–5.835) |
| T3/T4 (107)* | 99 (85.34) | 8 (6.9) | |
| Lymph node metastasis | |||
| Absent (6) | 5 (4.31) | 1 (0.86) | 0.392 (0.041–3.775) |
| Present (110)* | 102 (87.93) | 8 (6.9) | |
| Response to therapy | |||
| Sensitive (50) | 48 (41.38) | 2 (1.72) | 2.847 (0.565–14.345) |
| Resistant (66)* | 59 (50.86) | 7 (6.03) | |
| HR expression | |||
| Negative (62) | 55 (47.41) | 7 (6.03) | 0.302 (0.060–1.522) |
| Positive (54)* | 52 (44.83) | 2 (1.72) | |
| HER2 expression | |||
| Negative (107) | 63 (54.31) | 4 (3.45) | 1.790 (0.455–7.043) |
| Positive (9)* | 44 (37.93) | 5 (4.31) | |
| MYC expression | |||
| Negative (80) | 76 (65.52) | 4 (3.45) | 3.065 (0.771–12.176) |
| Positive (36)* | 31 (26.72) | 5 (4.31) | |
| HER2 amplification | |||
| Negative (88) | 84 (72.41) | 4 (3.45) | 4.565 (1.133–18,390)** |
| Positive (28)* | 23 (19.83) | 5 (4.31) | |
| MYC amplification | |||
| MYC/CEP8≤2.2 (103) | 97 (83.62) | 6 (5.17) | 4.850 (1.049–22.424)** |
| MYC/CEP8>2.2 (13)* | 10 (8.62) | 3 (2.59) | |
*
Reference group for logistic regression analysis; ** Differentially expressed between groups, p<0.05. N: number of samples; OR: odds ratio; CI: confidence interval. HR: hormone receptor; CEP8: chromosome 8 signals.